There are three million persons living with HCV in the U.S. Two of three are persons born 1945-1965; few are active injection drug users. Only 50% know of their infection; ~40% are in care and 12% placed on treatment. About 60% of HCV infected persons in care meet criteria for highest or high priority for treatment; ~1 in 4 are on Medicaid. New therapies are costly but increase benefits of testing and treatment. HCV testing and treatment can avert 120,000 deaths and is cost effective comparable to other preventive services (e.g. breast cancer screening). We must work together to address the cost and budgetary issues that limit access to HCV therapy.